TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pre-Implantation Genetic Screening in Women Under the Age of 36 With Single-Embryo Transfer
Brief Summary: BACKGROUND: Single-embryo transfer is a well-accepted strategy to avoid multiple pregnancies in an assisted reproductive technology programme. The selection of the embryo with the highest implantation potential is a crucial step. Besides the morphological quality and embryo kinetics up to the blastocyst stage, pre-implantation genetic screening (PGS) of aneuploidy has been advocated as an adjuvant approach by which to select the right embryo for transfer.

METHODS: Couples with a female partner younger than 36 years were randomly assigned to undergo transfer of a single blastocyst in a cycle with or without PGS using fluorescence in situ hybridization for the chromosomes X, Y, 13, 16, 18, 21 and 22.


Options:
A: Arm Label: Control (no PGD); Type: N/A; Interventions: N/A | Arm Label: Case (PGD); Type: N/A; Interventions: N/A
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Genetic: single embryo transfer without aneuploidy screening | Arm Label: B; Type: EXPERIMENTAL; Interventions: Genetic: single embryo transfer with aneuploidy screening | Intervention Type: GENETIC; Name: single embryo transfer without aneuploidy screening; Assigned to Arm(s): A | Intervention Type: GENETIC; Name: single embryo transfer with aneuploidy screening; Assigned to Arm(s): B
D: Arm Label: Single Embryo Transfer; Type: OTHER; Interventions: Other: Single Embryo Transfer | Arm Label: Double Embryo Transfer; Type: OTHER; Interventions: Other: Double embryo transfer | Intervention Type: OTHER; Name: Single Embryo Transfer; Assigned to Arm(s): Single Embryo Transfer | Intervention Type: OTHER; Name: Double embryo transfer; Assigned to Arm(s): Double Embryo Transfer

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo-controlled, Randomised, Double-blind Study to Investigate the Efficacy and Safety of Low Dose Hydrocortisone to Prevent the Development of Septic Shock in Patients With Severe Sepsis
Brief Summary: Severe sepsis is a disease with a high mortality. Development of shock is a most serious complication and increases the risk of death considerably. Application of low dose hydrocortisone is currently recommended only in patients after severe septic shock has been established. Hydrocortisone therapy has a hemodynamic stabilizing effect and may reverse shock, however, the preventive application has not been investigated in a larger study. The study investigates whether low dose hydrocortisone prevents the development of shock in patients with severe sepsis. It is postulated that shock prevention may also affect morbidity and mortality.


Options:
A: Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
B: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A
C: Arm Label: Hydrocortisone and fludrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone Fludrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Controlled; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone Fludrocortisone; Assigned to Arm(s): Hydrocortisone and fludrocortisone
D: Arm Label: H; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone | Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): H | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): P

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study.
Brief Summary: This prospective randomized double-blind placebo vs control study aims at verifying the efficacy of tranexamic acid administration in reducing perioperative bleeding in patients undergoing open radical prostatectomy. Two recent meta-analysis confirmed that tranexamic acid administration does not increase mortality, myocardial infarction, deep venous thrombosis, pulmonary embolism, stroke and renal failure.

200 patients undergoing open radical prostatectomy will be enrolled. Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.

Patients belonging to the control group will receive the same volume of saline infusions.


Options:
A: Arm Label: PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PCNL | Arm Label: mini-PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mini-PCNL | Arm Label: RIRS Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIRS | Intervention Type: PROCEDURE; Name: PCNL; Assigned to Arm(s): PCNL Group | Intervention Type: PROCEDURE; Name: mini-PCNL; Assigned to Arm(s): mini-PCNL Group | Intervention Type: PROCEDURE; Name: RIRS; Assigned to Arm(s): RIRS Group
B: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RIRS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde intrarenal surgery | Arm Label: PCNL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous nephrolithotomy | Intervention Type: PROCEDURE; Name: Percutaneous nephrolithotomy; Assigned to Arm(s): PCNL | Intervention Type: PROCEDURE; Name: Retrograde intrarenal surgery; Assigned to Arm(s): RIRS
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Brief Summary: This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.


Options:
A: Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo-fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg, Placebo-fingolimod
B: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri
Brief Summary: Aim: to assess relative effectiveness of a high and a low intensity intervention for smoking cessation support in a dental clinic setting.

Method: 300 smokers were randomly assigned to support with either low (LTI) or high treatment intensity (HTI).

Main outcome measures were self-reported point-prevalence and continuous abstinence (≥183 days).


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
B: Arm Label: 1 Nix Individual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nix Individual | Arm Label: 2 Fimpa dig fri; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fimpa dig fri | Intervention Type: BEHAVIORAL; Name: Nix Individual; Assigned to Arm(s): 1 Nix Individual | Intervention Type: BEHAVIORAL; Name: Fimpa dig fri; Assigned to Arm(s): 2 Fimpa dig fri
C: Arm Label: Champix plus counselling; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: counselling alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselling alone | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix plus counselling | Intervention Type: BEHAVIORAL; Name: Counselling alone; Assigned to Arm(s): counselling alone
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Dose adjustment of nicotine replacement therapies | Arm Label: 2; Type: OTHER; Interventions: Drug: nicotine patch | Intervention Type: PROCEDURE; Name: Dose adjustment of nicotine replacement therapies; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri
Brief Summary: Aim: to assess relative effectiveness of a high and a low intensity intervention for smoking cessation support in a dental clinic setting.

Method: 300 smokers were randomly assigned to support with either low (LTI) or high treatment intensity (HTI).

Main outcome measures were self-reported point-prevalence and continuous abstinence (≥183 days).


Options:
A: Arm Label: Lifestyle counseling; Type: OTHER; Interventions: Behavioral: Brief intervention | Intervention Type: BEHAVIORAL; Name: Brief intervention; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: CBP + PF; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Current Best Practices (CBP) | Arm Label: CBP + PF + P4P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Financial Incentive (P4P), Behavioral: Current Best Practices (CBP) | Arm Label: Current Best Practices (CBP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Current Best Practices (CBP) | Intervention Type: BEHAVIORAL; Name: Audit and performance feedback (PF); Assigned to Arm(s): CBP + PF, CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Financial Incentive (P4P); Assigned to Arm(s): CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Current Best Practices (CBP); Assigned to Arm(s): CBP + PF, CBP + PF + P4P, Current Best Practices (CBP)
C: Arm Label: 1 Nix Individual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nix Individual | Arm Label: 2 Fimpa dig fri; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fimpa dig fri | Intervention Type: BEHAVIORAL; Name: Nix Individual; Assigned to Arm(s): 1 Nix Individual | Intervention Type: BEHAVIORAL; Name: Fimpa dig fri; Assigned to Arm(s): 2 Fimpa dig fri
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri
Brief Summary: Aim: to assess relative effectiveness of a high and a low intensity intervention for smoking cessation support in a dental clinic setting.

Method: 300 smokers were randomly assigned to support with either low (LTI) or high treatment intensity (HTI).

Main outcome measures were self-reported point-prevalence and continuous abstinence (≥183 days).


Options:
A: Arm Label: Brief Advice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Advice (BA) | Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education (HE) | Intervention Type: BEHAVIORAL; Name: Brief Advice (BA); Assigned to Arm(s): Brief Advice | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Health Education (HE); Assigned to Arm(s): Health Education
B: Arm Label: Standard Care; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care | Arm Label: Motivational Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement; Assigned to Arm(s): Motivational Enhancement
C: Arm Label: Motivation Interviewing/CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing/CBT | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing/CBT; Assigned to Arm(s): Motivation Interviewing/CBT | Intervention Type: OTHER; Name: CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL); Assigned to Arm(s): Control
D: Arm Label: 1 Nix Individual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nix Individual | Arm Label: 2 Fimpa dig fri; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fimpa dig fri | Intervention Type: BEHAVIORAL; Name: Nix Individual; Assigned to Arm(s): 1 Nix Individual | Intervention Type: BEHAVIORAL; Name: Fimpa dig fri; Assigned to Arm(s): 2 Fimpa dig fri

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation
Brief Summary: This randomized trial compared the effectiveness of a three session pharmacist-delivered group program for smoking versus one 5 to 10 minute standard care session delivered over the telephone on 7-day point prevalence quit rates. Participants in both groups were offered their choice of bupropion IR or nicotine patch at no cost. At 6 months after the established quit date, self-reported cessation was biochemically verified using tests for urinary cotinine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist-delivered group program for smoking cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Brief standard care session for smoking cessation delivered over the telephone | Intervention Type: OTHER; Name: Pharmacist-delivered group program for smoking cessation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Brief standard care session for smoking cessation delivered over the telephone; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation
Brief Summary: This randomized trial compared the effectiveness of a three session pharmacist-delivered group program for smoking versus one 5 to 10 minute standard care session delivered over the telephone on 7-day point prevalence quit rates. Participants in both groups were offered their choice of bupropion IR or nicotine patch at no cost. At 6 months after the established quit date, self-reported cessation was biochemically verified using tests for urinary cotinine.


Options:
A: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
C: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist-delivered group program for smoking cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Brief standard care session for smoking cessation delivered over the telephone | Intervention Type: OTHER; Name: Pharmacist-delivered group program for smoking cessation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Brief standard care session for smoking cessation delivered over the telephone; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study
Brief Summary: The purpose of this study is to evaluate efficacy and safety of Polyunsaturated Fatty Acid for the prevention of Posttraumatic Stress Disorder (PTSD) in patients with accidental injuries.


Options:
A: Arm Label: Ketamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-Comparator | Intervention Type: DRUG; Name: Ketamine Hydrochloride; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Placebo-Comparator; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Polyunsaturated Fatty Acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): saline | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
D: Arm Label: Oxepa; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding., Dietary Supplement: oxepa | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: oxepa; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: Control group; Assigned to Arm(s): Control group

Answer: B